Mis-regulated NF-κB activity has been linked to human diseases encompassing inflammatory and autoimmune diseases and cancer4–7 and modulation of the NF-κB pathway has therefore been the focus for possible therapeutic development8,9. The gene discussed is NFKB1; the disease is autoimmune disease.